Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program
Top Cited Papers
- 1 August 2005
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes
- Vol. 54 (8), 2404-2414
- https://doi.org/10.2337/diabetes.54.8.2404
Abstract
Insulin resistance and β-cell dysfunction, two factors central to the pathogenesis of type 2 diabetes, were studied in relation to the development of diabetes in a group of participants with impaired glucose tolerance in the Diabetes Prevention Program (DPP) at baseline and after specific interventions designed to prevent diabetes. Participants were randomly assigned to placebo (n = 1,082), metformin (850 mg twice a day) (n = 1,073), or intensive lifestyle intervention (n = 1,079). The diabetes hazard rate was negatively associated with baseline insulin sensitivity (hazard rate ratio = 0.62–0.94 per SD difference, depending on treatment group and measure of sensitivity) and with baseline insulin secretion (hazard rate ratio = 0.57–0.76 per SD). Improvements in insulin secretion and insulin sensitivity were associated with lower hazard rates in all treatment arms (hazard rate ratio = 0.46–0.95 per SD increase and 0.29–0.79 per SD increase, respectively). In multivariate models that included the three metabolic variables (changes in body weight, insulin sensitivity, and insulin secretion) each significantly and independently predicted progression to diabetes when adjusted for the other two variables. The intensive lifestyle intervention, which elicited the greatest reduction in diabetes incidence, produced the greatest improvement in insulin sensitivity and the best preservation of β-cell function after 1 year, whereas the placebo group, which had the highest diabetes incidence, had no significant change in insulin sensitivity and β-cell function after 1 year. In the metformin group, diabetes risk, insulin sensitivity, and β-cell function at 1 year were intermediate between those in the intensive lifestyle and placebo groups. In conclusion, higher insulin secretion and sensitivity at baseline and improvements in response to treatment were associated with lower diabetes risk in the DPP. The better preventive effectiveness of intensive lifestyle may be due to improved insulin sensitivity concomitant with preservation of β-cell function.Keywords
This publication has 53 references indexed in Scilit:
- Pathways from obesity to diabetesInternational Journal of Obesity, 2002
- The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjectsDiabetes, 1997
- Understanding Oral Glucose Tolerance: Comparison of Glucose or Insulin Measurements During the Oral Glucose Tolerance Test with Specific Measurements of Insulin Resistance and Insulin SecretionDiabetic Medicine, 1994
- Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose toleranceJournal of Clinical Endocrinology & Metabolism, 1993
- Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up studyThe Lancet, 1992
- Epidemiological Correlates of NIDDM in Hispanics, Whites, and Blacks in the u.s. PopulationDiabetes Care, 1991
- The Natural History of Impaired Glucose Tolerance in the Pima IndiansNew England Journal of Medicine, 1988
- Impaired Glucose Tolerance as a Disorder of Insulin ActionNew England Journal of Medicine, 1988
- The Whitehall Study: Ten Year Follow‐up Report on Men With Impaired Glucose Tolerance With Reference to Worsening to Diabetes and Predictors of DeathDiabetic Medicine, 1984
- Major factors in the development of diabetes mellitus in 10,000 menArchives of Internal Medicine, 1975